Iranian Journal of Diabetes and Obesity
Shahid Sadoughi University Of Medical Sciences
Mon, Nov 25, 2024
[Archive]
Volume 10, Issue 1 (3-2018)
IJDO 2018, 10(1): 1-10 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bahrami D, Mozaffari-Khosravi H. The Effect of Oral L-arginine Supplementation on Blood Pressure in Patients with Metabolic Syndrome: A Randomized Clinical Trial. IJDO 2018; 10 (1) :1-10
URL: http://ijdo.ssu.ac.ir/article-1-378-en.html
URL: http://ijdo.ssu.ac.ir/article-1-378-en.html
Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Abstract: (3110 Views)
Objective: Hypertension is a common component of metabolic syndrome (MetS). Some studies showed that L-arginine reduced the blood pressure (BP) .Therefore this study was designed to evaluate the effect of L-arginine supplementation on BP in MetS.
Materials and Methods: In this randomized, double-blind, placebo-controlled trials, 60 patients with MetS were randomly divided into two groups: the L-arginine-supplemented group (AG), who received 5 gr of L-arginine daily and placebo group (PG). Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), pulse pressure (PP) were measured before and after the intervention and compared.
Results: At the end of the study in the AG significant reductions were observed in the SBP, DBP and MAP (P-value:0.001).The comparison of changes in variables between the AG and PG indicated that in the AG, patients had a significantly greater decrease in the SBP (-11.25±10.93 vs. -2.67±6.15 mmHg: P-value:0.001), DBP(-5.71±7.16 vs. -1.25±7.02 mmHg: p-value: 0.02) and MAP (-7.55±5.61 vs.-1.72±5.16 mmHg, P-value: 0.001). The PP decreased in both groups but a significant decrease compared with baseline in the AG was observed (-5.53±13.83 vs. -1.42±9.21 mmHg: P-value: 0.19).
Conclusion: The findings of the present study showed that 5 gr/d L- arginine supplementation for 12 weeks in MetS resulted in significant decrease in the SBP, DBP and MAP but had no significant effect on the PP.
Materials and Methods: In this randomized, double-blind, placebo-controlled trials, 60 patients with MetS were randomly divided into two groups: the L-arginine-supplemented group (AG), who received 5 gr of L-arginine daily and placebo group (PG). Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), pulse pressure (PP) were measured before and after the intervention and compared.
Results: At the end of the study in the AG significant reductions were observed in the SBP, DBP and MAP (P-value:0.001).The comparison of changes in variables between the AG and PG indicated that in the AG, patients had a significantly greater decrease in the SBP (-11.25±10.93 vs. -2.67±6.15 mmHg: P-value:0.001), DBP(-5.71±7.16 vs. -1.25±7.02 mmHg: p-value: 0.02) and MAP (-7.55±5.61 vs.-1.72±5.16 mmHg, P-value: 0.001). The PP decreased in both groups but a significant decrease compared with baseline in the AG was observed (-5.53±13.83 vs. -1.42±9.21 mmHg: P-value: 0.19).
Conclusion: The findings of the present study showed that 5 gr/d L- arginine supplementation for 12 weeks in MetS resulted in significant decrease in the SBP, DBP and MAP but had no significant effect on the PP.
Type of Study: Research |
Subject:
Special
Received: 2018/05/12 | Accepted: 2018/05/12 | Published: 2018/05/12
Received: 2018/05/12 | Accepted: 2018/05/12 | Published: 2018/05/12
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
